- Previous Rank17
- Revenue 3 Yr Annual Growth Rate32%
- Revenue 3 Yr Growth Rank48
- EPS 3 Yr Annual Growth Rate58%
- EPS 3 Yr Growth Rank30
- Total Return 3 Yr Annual Rate-4%
- Total Return 3 Yr Rank96
Hepatitis C treatments are an integral part of the biotech’s product line. Recent approval for a competitor’s comprehensive Hep C drug adds new pressure.
Company Information
Revenue and net income for the four quarters ended on or before April 30, 2017. Total return for the period ended June 30, 2017.
Location | Foster City, Calif. |
Industry | Pharmaceuticals |
Sector | Health Care |
Current Streak | 3 |
Years on List | 8 |
CEO | John Milligan |
Website | http://www.gilead.com |
Revenue, Net Income
Revenue past four quarters ($M) | $29,101 |
Net Income past four quarters ($M) | $12,637 |
Growth Rates and Ranks
Revenue 3 Yr Growth Rank | 48 |
Revenue 3 Yr Annual Growth Rate | 32% |
EPS 3 Yr Growth Rank | 30 |
EPS 3 Yr Annual Growth Rate | 58% |
Total Return 3 Yr Rank | 96 |
Total Return 3 Yr Annual Rate | -4% |
Beat S&P 500 (9.6%) | no |
P/E Ratio | 9 |